mCancerPartner interviewed Dan Hayes, M.D., clinical director of the Cancer Center’s breast oncology program. In late September 2015, investigators – including Dr. Hayes – showed that many women with early stage breast cancer can skip chemotherapy with good results, based on a gene test assessing which tumors were more likely to respond to chemotherapy. This study validates clinical recommendations in place since 2007 made by the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Dr. Hayes served on both recommendation task forces and provided the following remarks on the origin of these recommendations.
mCancerPartner: How has the standard of care for women with the most common type of breast cancer (early stage, hormone positive, HER2 negative, not spread to lymph nodes) evolved over the years? Continue reading
Editor’s note: This is part of a series of blogs that focus on members of the Pancreatic Cancer Research Center. Led by an inter-disciplinary team of scientists and clinicians, the Center holds the promise to significantly change the bleak statistics associated with this disease by revolutionizing pancreatic cancer care. One therapeutic tool they are advancing involves gathering pancreatic cancer cells from the bloodstream, assembling them into replicas of a patient’s tumor and testing various drug combinations on the copies to develop personalized medicine for each patient.
Pancreatic cancer patients are getting closer to the day when a small amount of their own blood will provide enough information so that doctors can recommend personalized treatments targeting the whole tumor. If you ask Diane Simeone, M.D., the Lazar J. Greenfield Professor of Surgery and director of the Pancreatic Cancer Center, this vision of the future may become reality in the next five years. Continue reading
Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses in 2014. The most common type of lung cancer, non-small cell lung cancer or NSCLC, affects seven out of eight lung cancer patients.
In October 2015, the U.S. Food and Drug Administration approved Opdivo® (Nivolumab) and Keytruda® (Pembrolizumab) to treat patients with advanced, or metastatic, NSCLC. Both medicines stimulate a patient’s own immune system to destroy cancer cells.
At the University of Michigan’s Multidisciplinary Lung Cancer Clinic, we are using both drugs in appropriate patients as standard of care. We also have other similar immunotherapy drugs in a variety of clinical trials.
As scary as these symptoms might be, many of the signs and symptoms of liver cancer can also be caused by other conditions, including other liver problems or even a vitamin overdose. None-the-less, yellowing of the skin and eyes, along with weight loss, itchy skin and feeling tired are some of the symptoms of liver cancer. By the time these symptoms occur, the disease may have already spread. That’s why it is so important to see your doctor right away if you have these symptoms, so the cause can be found and treated. Continue reading
Chances are, the treatment plan for your cancer was determined by the results on a pathology report. Before your diagnosis, you probably had a biopsy or surgery where a doctor removed cells or tissue for study under a microscope. Specialists called pathologists spend their days viewing these samples, understanding how they look compared to normal cells and preparing reports which summarize the findings on each biopsy for oncologists and surgeons.
We spoke with Cancer Center pathologist, Celina Kleer, M.D., director of the Breast Pathology Division in the Department of Pathology,to find out the information contained in a report and how your oncologist uses it to decide the best course of treatment for your cancer. Continue reading